Biogen Inc. Dividend History (BIIB)
Biogen Inc. does not pay dividends currently 😔
They might in the future, check back soon!
About Biogen Inc.
Biogen Inc. is a leading American biotechnology company founded in 1978. It focuses on discovering, developing, and delivering innovative therapies for the treatment of neurological diseases. Biogen is renowned for its work in areas like multiple sclerosis (MS) and Alzheimer's disease. Headquartered in Cambridge, Massachusetts, the company is dedicated to using pioneering research to improve health outcomes for patients worldwide. As of now, the CEO is Christopher A. Viehbacher, who took the helm in November 2022. Biogen is also recognized for its commitment to sustainability and scientific excellence. In 2022, the company reported a revenue of approximately $10 billion, showcasing its substantial impact in the biotech sector. Through strategic partnerships and a robust product pipeline, Biogen aims to address some of the most challenging unmet medical needs.
Amgen Inc.
Bristol-Myers Squibb Company
Cassava Sciences, Inc.
Eli Lilly and Company
Gilead Sciences, Inc.
Ionis Pharmaceuticals, Inc.
Moderna, Inc.
Prothena Corporation plc
Sage Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated
The cancer monoclonal antibodies market is projected to grow at a CAGR of 18.4% to reach $337.92 billion by 2031, driven by the high incidence of cancer and advancements in biotechnology. The rising use of combination therapies and biosimilars is also expected to create new opportunities for companies in this market.
Benzinga · Published on Mon Dec 09 2024CD40 targeted therapies represent a promising and rapidly developing area of research across various diseases, with several candidates in late-stage clinical trials. The market is expected to grow as these therapies potentially become a vital treatment option in the coming years.
GlobeNewswire Inc. · Published on Mon Dec 09 2024
The article discusses the worst-performing stocks in the Nasdaq-100 index so far in 2022, emphasizing that investors should not abandon long-term investments due to short-term slumps. It suggests considering the underlying reasons for the price declines and maintaining a long-term perspective.
The Motley Fool · Published on Tue Nov 26 2024